Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Pfizer

Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.

Even amid volatility, Pfizer keeps rewarding shareholders year after year.

Barchart

Health Care Stocks Have Sagged. Can You Bet on a Recovery?

The flagging health care sector has perked up a bit lately. Is it time to invest?

Kiplinger

COVID-19 Vaccine Updates 2026: Booster Shots, Effectiveness, and Expert Guidance

COVID vaccines and booster shots 2025–2026 offer 80–95% protection against JN.1 and KP.2 variants, reducing severe illness and hospitalization.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

UK law firms consider action on behalf of women who developed brain tumours after using contraceptive

Studies show Depo-Provera users have much higher relative risk of developing meningiomas, although overall risk remains low

The Guardian - UK

Pfizer Reports Strong Earnings Outlook - Unusual Call Options Activity Shows Investors are Bullish

Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish.

Barchart

Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential

Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer options investors significant profit potential. Volatility returned to markets yesterday, triggering a tech rout. Among the…

Barchart

Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most

Pfizer stock jumped after a strong earnings beat and positive GLP-1 data, but investors may be overlooking a powerful oncology and AI-driven growth story.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

New weight loss drug by Pfizer shows promising results in trial

Pfizer acquired the drug’s developer following a bidding war with Novo Nordisk last year

The Independent UK

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

Barchart

How Pfizer’s CEO wielded moral clarity to help his team do the impossible

The pharma company had to scale vaccine production from 200 million annually to 3 billion at the pandemic's peak.

Fortune

Pfizer CEO Albert Bourla's best leadership advice: Being optimistic is better than being right

Albert Bourla, the boss of the $150 billion pharmaceutical giant Pfizer, admits leaders don’t win by always being right—the key is being someone your peers want to follow.

Fortune

'We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post‑COVID bet on oncology

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The winners always stand up again."

Fortune

Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 pandemic.

Fortune

7 Prescription Price Increases Linked to Supplier Changes

We often assume drug prices rise solely due to corporate greed or inflation. In 2026, a different force is driving costs up. Structural changes in...

Saving Advice

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Pfizer’s CEO on leading after a moonshot—and making deals with Trump

Also: All the news and watercooler chat from Fortune.

Barchart

What Are Wall Street Analysts' Target Price for Pfizer Stock?

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

MarketBeat

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

We Got This Covered

Today in ‘great’ America: Donald Trump decides to prove he can’t negotiate to save his life

What an awful deal.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

Barchart

Unusual Options Activity in Pfizer: 2 Strategies Traders Are Jumping On

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at 210.16. In the money by 12.8%, it sets up for a couple of different trading strategies.

Medical Daily

COVID Nimbus Explained: Key Symptoms, Warning Signs, and What You Need to Know

Get essential facts on COVID Nimbus (NB.1.8.1) symptoms, transmission, risk groups, prevention, and treatment to stay informed and protect your health.

MarketBeat

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever

With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.

The Independent UK

Despite Trump pressure, Big Pharma is raising hundreds of drug prices

Costs of at least 350 branded medications, including vaccines against Covid-19, shingles and cancer treatment Ibrance, will reportedly be hiked

MarketBeat

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.

Kiplinger

Stocks Chop as the Unemployment Rate Jumps: Stock Market Today

November job growth was stronger than expected, but sharp losses in October and a rising unemployment rate are worrying market participants.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.